Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial

被引：0
|
作者：
Hans-Joachim Schmoll
Julia Mann
Fabian Meinert
Benjamin Garlipp
Kersten Borchert
Arndt Vogel
Eray Goekkurt
Ulrich Kaiser
Heinz-Gert Hoeffkes
Jörn Rüssel
Stephan Kanzler
Thomas Edelmann
Helmut Forstbauer
Thomas Göhler
Carla Hannig
Bert Hildebrandt
Carsten Roll
Carsten Bokemeyer
Jörg Steighardt
Franziska Cygon
Stefan Ibach
Alexander Stein
Joseph Tintelnot
机构：
[1] University Clinic,Clinic for Internal Medicine IV—Hematology/Oncology
[2] Martin-Luther-University,Department of Medicine, Hematology and BMT with section Pneumology, University Cancer Center Hamburg
[3] University Medical Center Hamburg-Eppendorf,Department for Surgery
[4] Oberhavel Kliniken Oranienburg,Clinic for Gastroenterology
[5] Clinic for Oncology/Hematology Klinikum Magdeburg,Clinic for Hematology/Oncology
[6] Medical University Hannover,Tumorclinic
[7] St. Bernward Krankenhaus,Medical Clinic II
[8] Klinikum Fulda,Clinic for Gastroenterology, Hematology and Medical Oncology
[9] Leopoldina Clinic Schweinfurt,Coordination Center for Clinical Trials Halle, Medical Faculty
[10] Oncological Practice Schkeuditz,undefined
[11] Oncological Practice Rheinsieg,undefined
[12] Oncological Center Dresden,undefined
[13] Oncological Practice Bottrop,undefined
[14] Klinikum Barnim,undefined
[15] Martin-Luther-University,undefined
[16] X-act Cologne Clinical Research GmbH,undefined
来源：
British Journal of Cancer | 2024年 / 130卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：233 / 241
页数：8
相关论文
共 50 条
  • [1] Efficacy and quality of life for FOLFOX/bevacizumab plus /- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial
    Schmoll, Hans-Joachim
    Mann, Julia
    Meinert, Fabian
    Garlipp, Benjamin
    Borchert, Kersten
    Vogel, Arndt
    Goekkurt, Eray
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Roll, Carsten
    Bokemeyer, Carsten
    Steighardt, Joerg
    Cygon, Franziska
    Ibach, Stefan
    Stein, Alexander
    Tintelnot, Joseph
    [J]. BRITISH JOURNAL OF CANCER, 2024, 130 (02) : 233 - 241
  • [2] FOLFOX/Bevacizumab plus /- Irinotecan in advanced colorectal cancer (AIO) "CHARTA": Final results and multivariate prognostic factor analysis
    Hans-Joachim, Schmoll
    Benjamin, Garlipp
    Christian, Junghanss
    Malte, Leithaeuser
    Arndt, Vogel
    Michael, Schaefers
    Ulrich, Kaiser
    Heinz-Gert, Hoeffkes
    Axel, Florschuetz
    Joern, Ruessel
    Stephan, Kanzler
    Thomas, Edelmann
    Helmut, Forstbauer
    Thomas, Goehler
    Carla, Hannig
    Bert, Hildebrandt
    Joerg, Steighardt
    Franziska, Cygon
    Fabian, Meinert
    Alexander, Stein
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [3] CHARTA: FOLFOX plus bevacizumab plus /- irinotecan in advanced colorectal cancer (CRC)-Final results of the randomized phase II trial of the AIO (KRK 0209).
    Schmoll, Hans-Joachim
    Garlipp, Benjamin
    Junghanss, Christian
    Leithaeuser, Malte
    Vogel, Arndt
    Schaefers, Michael
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Florschuetz, Axel
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Steighardt, Joerg
    Meinert, Fabian Maximilian
    Cygon, Franziska
    Stein, Alexander
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Impact of first line FOLFOXIRI and Bevacizumab (Bev) compared to FOLFOX and Bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRCR) - analysis of the CHARTA - AIO 0209 trial
    Quidde, J.
    Nilsson, S.
    Schmoll, H. -J.
    Garlipp, B.
    Junghanss, C.
    Leithaeuser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. -G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Roll, C.
    Steighardt, J.
    Stein, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 208 - 208
  • [5] Predicting resistance to first-line FOLFOX plus bevacizumab in metastatic colorectal cancer: Final results of the multicenter, international PERMAD trial.
    Seufferlein, Thomas
    Ettrich, Thomas Jens
    Stein, Alexander
    Arnold, Dirk
    Prager, Gerald W.
    Kasper, Stefan
    Niedermeier, Michael
    Muller, Lothar
    Kubicka, Stefan
    Koenig, Alexander
    Buchner-Steudel, Petra
    Wille, Kai
    Kestler, Angelika M. R.
    Berger, Andreas W.
    Perkhofer, Lukas
    Lausser, Ludwig
    Kestler, Hans A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [6] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    [J]. VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [7] FOLFOX / Bevacizumab (Beva) plus /- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)
    Schmoll, H. J.
    Garlipp, B.
    Junghanss, C.
    Leithauser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Steighardt, J.
    Meinert, F. M.
    Cygon, F.
    Stein, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT
    Berry, S. R.
    Van Cutsem, E.
    Kretzschmar, A.
    Michael, M.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M. A.
    Andre, N.
    Cunningham, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ueno, Masashi
    Yamaguchi, Toshiharu
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 322 - 329
  • [10] Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
    Van Cutsem, E.
    Rivera, F.
    Berry, S.
    Kretzschmar, A.
    Michael, M.
    DiBartolomeo, M.
    Mazier, M. -A.
    Canon, J. -L.
    Georgoulias, V.
    Peeters, M.
    Bridgewater, J.
    Cunningham, D.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (11) : 1842 - 1847
12345